what the broker likes:
1. Fast path to market. Formerly a Johnson & Johnson (J&J) developmental cancer drug, ISLA-101 has been through 48x Phase I and II clinical trials before being re-purposed - verified safe in humans by multiple regulators (including the FDA, twice)
2. Strong initial efficacy data. Promising results in human and animal studies for dengue, Zika & other viruses.
3. Very large target market. ~390m humans are infected with dengue fever alone each year (up to 50% with no symptoms) – significant revenue potential
4. Eligible for a Priority Review Voucher (PRV) for each of dengue, Zika and Chikungunya (= 3x “shots on goal”) – average sale price of a PRV ~US$100m; up to US$350m (not reflected in Island IPO valuation)
5. IPO valuation of $12.5m (pre-money) vs list peer mkt caps of:Anti-virals: Starpharma ($590m), Biotron ($57m)Re-purposed drugs: Paradigm Biopharmaceuticals ($541m), PharmAust ($32m), Race Oncology ($240m)PRV-eligible drugs: Kazia Therapeutics ($170m), Race Oncology ($240m)
- Forums
- IPOs
- Island Pharmaceuticals IPO
what the broker likes:1. Fast path to market. Formerly a Johnson...
-
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ILA (ASX) to my watchlist
|
|||||
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.240M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 6.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.9¢ | 59999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.064 |
1 | 63134 | 0.061 |
2 | 13127 | 0.060 |
1 | 18181 | 0.055 |
1 | 150000 | 0.054 |
Price($) | Vol. | No. |
---|---|---|
0.069 | 59999 | 1 |
0.070 | 6582 | 1 |
0.074 | 4000 | 1 |
0.075 | 139129 | 2 |
0.076 | 620 | 1 |
Last trade - 10.04am 15/08/2024 (20 minute delay) ? |
Featured News
ILA (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online